ERBB2 and cancer: Thus, targeting molecular drivers involved in the CSC program, including the dysregulated expression/activation of HER2 and its splice variant d16HER2 in HER2+ breast [9–12] and gastric [13–15] cancers, may improve cancer patient outcomes, yielding long-lasting responses [16].